Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02554812 · FLOW

Participant flow

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) · Source last updated 2024-07-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    During phase 1b participants with Non-Small Cell Lung Cancer (NSCLC) received utomilumab 500 mg intravenously (IV) every 4 weeks (Q4W) with 10 milligrams per kilogram (mg/kg) of avelumab administered IV every 2 weeks (Q2W) for 2 cycles, where each cycle was of 4 weeks.
    id
    FG000
    title
    Combination A Phase 1b NSCLC: Utomilumab 500 mg + Avelumab
  2. description
    During phase 1b participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
    id
    FG001
    title
    Combination A Phase 1b NSCLC: Utomilumab 100 mg + Avelumab
  3. description
    During phase 1b participants with NSCLC received utomilumab 20 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
    id
    FG002
    title
    Combination A Phase 1b NSCLC: Utomilumab 20 mg + Avelumab
  4. description
    During Phase 2 participants with melanoma received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
    id
    FG003
    title
    Combination A Phase 2 Melanoma: Utomilumab 100 mg + Avelumab
  5. description
    During Phase 2 participants with Squamous Cell Carcinoma of the Head and Neck (SCCHN) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
    id
    FG004
    title
    Combination A Phase 2 SCCHN: Utomilumab 100 mg + Avelumab
  6. description
    During Phase 2 participants with Triple Negative Breast Cancer (TNBC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
    id
    FG005
    title
    Combination A Phase 2 TNBC: Utomilumab 100 mg + Avelumab
  7. description
    During Phase 2 participants with Squamous cell lung cancer (SCLC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
    id
    FG006
    title
    Combination A Phase 2 SCLC: Utomilumab 100 mg + Avelumab
  8. description
    During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
    id
    FG007
    title
    Combination A Phase 2 First Line (1L) NSCLC: Utomilumab 100 mg + Avelumab
  9. description
    During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W for cycle 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.
    id
    FG008
    title
    Combination A Phase 2 1L NSCLC: Utomilumab Then Utomilumab + Avelumab
  10. description
    During Phase 2 participants with NSCLC received avelumab 10 mg/kg administered IV Q2W for cycles 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.
    id
    FG009
    title
    Combination A Phase 2 1L NSCLC: Avelumab Then Utomilumab + Avelumab
  11. description
    During Phase 1b participants received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.
    id
    FG010
    title
    Combination B Phase 1b: PF-04518600 0.3 mg/kg + Avelumab
  12. description
    During Phase 1b participants received PF-04518600 1.0 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.
    id
    FG011
    title
    Combination B Phase 1b: PF-04518600 1.0 mg/kg + Avelumab
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        5
      3. group Id
        FG002
        num Subjects
        3
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        5
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        1
      8. group Id
        FG007
        num Subjects
        6
      9. group Id
        FG008
        num Subjects
        2
      10. group Id
        FG009
        num Subjects
        2
      11. group Id
        FG010
        num Subjects
        1
      12. group Id
        FG011
        num Subjects
        2
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        2
      3. group Id
        FG002
        num Subjects
        2
      4. group Id
        FG003
        num Subjects
        2
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        1
      7. group Id
        FG006
        num Subjects
        1
      8. group Id
        FG007
        num Subjects
        1
      9. group Id
        FG008
        num Subjects
        0
      10. group Id
        FG009
        num Subjects
        0
      11. group Id
        FG010
        num Subjects
        0
      12. group Id
        FG011
        num Subjects
        0
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      9. group Id
        FG008
        num Subjects
        0
      10. group Id
        FG009
        num Subjects
        0
      11. group Id
        FG010
        num Subjects
        0
      12. group Id
        FG011
        num Subjects
        0
      type
      Lost to Follow-up
    4. reasons
      1. group Id
        FG000
        num Subjects
        4
      2. group Id
        FG001
        num Subjects
        3
      3. group Id
        FG002
        num Subjects
        3
      4. group Id
        FG003
        num Subjects
        2
      5. group Id
        FG004
        num Subjects
        5
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        2
      8. group Id
        FG007
        num Subjects
        1
      9. group Id
        FG008
        num Subjects
        1
      10. group Id
        FG009
        num Subjects
        1
      11. group Id
        FG010
        num Subjects
        2
      12. group Id
        FG011
        num Subjects
        1
      type
      Global deterioration of health status
    5. reasons
      1. group Id
        FG000
        num Subjects
        20
      2. group Id
        FG001
        num Subjects
        16
      3. group Id
        FG002
        num Subjects
        19
      4. group Id
        FG003
        num Subjects
        18
      5. group Id
        FG004
        num Subjects
        21
      6. group Id
        FG005
        num Subjects
        15
      7. group Id
        FG006
        num Subjects
        6
      8. group Id
        FG007
        num Subjects
        13
      9. group Id
        FG008
        num Subjects
        6
      10. group Id
        FG009
        num Subjects
        6
      11. group Id
        FG010
        num Subjects
        8
      12. group Id
        FG011
        num Subjects
        8
      type
      Progressive disease
    6. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        2
      4. group Id
        FG003
        num Subjects
        3
      5. group Id
        FG004
        num Subjects
        2
      6. group Id
        FG005
        num Subjects
        1
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      9. group Id
        FG008
        num Subjects
        1
      10. group Id
        FG009
        num Subjects
        1
      11. group Id
        FG010
        num Subjects
        0
      12. group Id
        FG011
        num Subjects
        0
      type
      Other
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        2
      5. group Id
        FG004
        num Subjects
        2
      6. group Id
        FG005
        num Subjects
        3
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      9. group Id
        FG008
        num Subjects
        1
      10. group Id
        FG009
        num Subjects
        1
      11. group Id
        FG010
        num Subjects
        0
      12. group Id
        FG011
        num Subjects
        1
      type
      Withdrawal by Subject
    8. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        1
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        1
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      9. group Id
        FG008
        num Subjects
        0
      10. group Id
        FG009
        num Subjects
        0
      11. group Id
        FG010
        num Subjects
        1
      12. group Id
        FG011
        num Subjects
        0
      type
      Physician Decision
    9. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      9. group Id
        FG008
        num Subjects
        0
      10. group Id
        FG009
        num Subjects
        0
      11. group Id
        FG010
        num Subjects
        0
      12. group Id
        FG011
        num Subjects
        0
      type
      Study terminated by sponsor
    10. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      9. group Id
        FG008
        num Subjects
        0
      10. group Id
        FG009
        num Subjects
        0
      11. group Id
        FG010
        num Subjects
        0
      12. group Id
        FG011
        num Subjects
        0
      type
      No longer meets eligibility criteria
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        29
      2. group Id
        FG001
        num Subjects
        28
      3. group Id
        FG002
        num Subjects
        29
      4. group Id
        FG003
        num Subjects
        28
      5. group Id
        FG004
        num Subjects
        35
      6. group Id
        FG005
        num Subjects
        21
      7. group Id
        FG006
        num Subjects
        10
      8. group Id
        FG007
        num Subjects
        21
      9. group Id
        FG008
        num Subjects
        11
      10. group Id
        FG009
        num Subjects
        11
      11. group Id
        FG010
        num Subjects
        12
      12. group Id
        FG011
        num Subjects
        12
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        29
      2. group Id
        FG001
        num Subjects
        27
      3. group Id
        FG002
        num Subjects
        29
      4. group Id
        FG003
        num Subjects
        28
      5. group Id
        FG004
        num Subjects
        35
      6. group Id
        FG005
        num Subjects
        21
      7. group Id
        FG006
        num Subjects
        10
      8. group Id
        FG007
        num Subjects
        21
      9. group Id
        FG008
        num Subjects
        11
      10. group Id
        FG009
        num Subjects
        11
      11. group Id
        FG010
        num Subjects
        12
      12. group Id
        FG011
        num Subjects
        12
      type
      Treated
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      9. group Id
        FG008
        num Subjects
        0
      10. group Id
        FG009
        num Subjects
        0
      11. group Id
        FG010
        num Subjects
        0
      12. group Id
        FG011
        num Subjects
        0
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        29
      2. group Id
        FG001
        num Subjects
        28
      3. group Id
        FG002
        num Subjects
        29
      4. group Id
        FG003
        num Subjects
        28
      5. group Id
        FG004
        num Subjects
        35
      6. group Id
        FG005
        num Subjects
        21
      7. group Id
        FG006
        num Subjects
        10
      8. group Id
        FG007
        num Subjects
        21
      9. group Id
        FG008
        num Subjects
        11
      10. group Id
        FG009
        num Subjects
        11
      11. group Id
        FG010
        num Subjects
        12
      12. group Id
        FG011
        num Subjects
        12
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
In this study participants were evaluated in 5 different combinations with avelumab: Combination A, B, C, D and F. Each combination was planned to be conducted in 2 phases: Phase 1b (lead-in phase) and Phase 2 (expansion phase). Phase 2 was conducted at the selected dose level of avelumab combination which was determined safe for participants in Phase 1b.
Complete source fields
groups
  1. description
    During phase 1b participants with Non-Small Cell Lung Cancer (NSCLC) received utomilumab 500 mg intravenously (IV) every 4 weeks (Q4W) with 10 milligrams per kilogram (mg/kg) of avelumab administered IV every 2 weeks (Q2W) for 2 cycles, where each cycle was of 4 weeks.
    id
    FG000
    title
    Combination A Phase 1b NSCLC: Utomilumab 500 mg + Avelumab
  2. description
    During phase 1b participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
    id
    FG001
    title
    Combination A Phase 1b NSCLC: Utomilumab 100 mg + Avelumab
  3. description
    During phase 1b participants with NSCLC received utomilumab 20 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
    id
    FG002
    title
    Combination A Phase 1b NSCLC: Utomilumab 20 mg + Avelumab
  4. description
    During Phase 2 participants with melanoma received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
    id
    FG003
    title
    Combination A Phase 2 Melanoma: Utomilumab 100 mg + Avelumab
  5. description
    During Phase 2 participants with Squamous Cell Carcinoma of the Head and Neck (SCCHN) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
    id
    FG004
    title
    Combination A Phase 2 SCCHN: Utomilumab 100 mg + Avelumab
  6. description
    During Phase 2 participants with Triple Negative Breast Cancer (TNBC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
    id
    FG005
    title
    Combination A Phase 2 TNBC: Utomilumab 100 mg + Avelumab
  7. description
    During Phase 2 participants with Squamous cell lung cancer (SCLC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
    id
    FG006
    title
    Combination A Phase 2 SCLC: Utomilumab 100 mg + Avelumab
  8. description
    During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
    id
    FG007
    title
    Combination A Phase 2 First Line (1L) NSCLC: Utomilumab 100 mg + Avelumab
  9. description
    During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W for cycle 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.
    id
    FG008
    title
    Combination A Phase 2 1L NSCLC: Utomilumab Then Utomilumab + Avelumab
  10. description
    During Phase 2 participants with NSCLC received avelumab 10 mg/kg administered IV Q2W for cycles 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.
    id
    FG009
    title
    Combination A Phase 2 1L NSCLC: Avelumab Then Utomilumab + Avelumab
  11. description
    During Phase 1b participants received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.
    id
    FG010
    title
    Combination B Phase 1b: PF-04518600 0.3 mg/kg + Avelumab
  12. description
    During Phase 1b participants received PF-04518600 1.0 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.
    id
    FG011
    title
    Combination B Phase 1b: PF-04518600 1.0 mg/kg + Avelumab
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        5
      3. group Id
        FG002
        num Subjects
        3
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        5
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        1
      8. group Id
        FG007
        num Subjects
        6
      9. group Id
        FG008
        num Subjects
        2
      10. group Id
        FG009
        num Subjects
        2
      11. group Id
        FG010
        num Subjects
        1
      12. group Id
        FG011
        num Subjects
        2
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        2
      3. group Id
        FG002
        num Subjects
        2
      4. group Id
        FG003
        num Subjects
        2
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        1
      7. group Id
        FG006
        num Subjects
        1
      8. group Id
        FG007
        num Subjects
        1
      9. group Id
        FG008
        num Subjects
        0
      10. group Id
        FG009
        num Subjects
        0
      11. group Id
        FG010
        num Subjects
        0
      12. group Id
        FG011
        num Subjects
        0
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      9. group Id
        FG008
        num Subjects
        0
      10. group Id
        FG009
        num Subjects
        0
      11. group Id
        FG010
        num Subjects
        0
      12. group Id
        FG011
        num Subjects
        0
      type
      Lost to Follow-up
    4. reasons
      1. group Id
        FG000
        num Subjects
        4
      2. group Id
        FG001
        num Subjects
        3
      3. group Id
        FG002
        num Subjects
        3
      4. group Id
        FG003
        num Subjects
        2
      5. group Id
        FG004
        num Subjects
        5
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        2
      8. group Id
        FG007
        num Subjects
        1
      9. group Id
        FG008
        num Subjects
        1
      10. group Id
        FG009
        num Subjects
        1
      11. group Id
        FG010
        num Subjects
        2
      12. group Id
        FG011
        num Subjects
        1
      type
      Global deterioration of health status
    5. reasons
      1. group Id
        FG000
        num Subjects
        20
      2. group Id
        FG001
        num Subjects
        16
      3. group Id
        FG002
        num Subjects
        19
      4. group Id
        FG003
        num Subjects
        18
      5. group Id
        FG004
        num Subjects
        21
      6. group Id
        FG005
        num Subjects
        15
      7. group Id
        FG006
        num Subjects
        6
      8. group Id
        FG007
        num Subjects
        13
      9. group Id
        FG008
        num Subjects
        6
      10. group Id
        FG009
        num Subjects
        6
      11. group Id
        FG010
        num Subjects
        8
      12. group Id
        FG011
        num Subjects
        8
      type
      Progressive disease
    6. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        2
      4. group Id
        FG003
        num Subjects
        3
      5. group Id
        FG004
        num Subjects
        2
      6. group Id
        FG005
        num Subjects
        1
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      9. group Id
        FG008
        num Subjects
        1
      10. group Id
        FG009
        num Subjects
        1
      11. group Id
        FG010
        num Subjects
        0
      12. group Id
        FG011
        num Subjects
        0
      type
      Other
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        2
      5. group Id
        FG004
        num Subjects
        2
      6. group Id
        FG005
        num Subjects
        3
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      9. group Id
        FG008
        num Subjects
        1
      10. group Id
        FG009
        num Subjects
        1
      11. group Id
        FG010
        num Subjects
        0
      12. group Id
        FG011
        num Subjects
        1
      type
      Withdrawal by Subject
    8. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        1
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        1
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      9. group Id
        FG008
        num Subjects
        0
      10. group Id
        FG009
        num Subjects
        0
      11. group Id
        FG010
        num Subjects
        1
      12. group Id
        FG011
        num Subjects
        0
      type
      Physician Decision
    9. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      9. group Id
        FG008
        num Subjects
        0
      10. group Id
        FG009
        num Subjects
        0
      11. group Id
        FG010
        num Subjects
        0
      12. group Id
        FG011
        num Subjects
        0
      type
      Study terminated by sponsor
    10. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      9. group Id
        FG008
        num Subjects
        0
      10. group Id
        FG009
        num Subjects
        0
      11. group Id
        FG010
        num Subjects
        0
      12. group Id
        FG011
        num Subjects
        0
      type
      No longer meets eligibility criteria
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        29
      2. group Id
        FG001
        num Subjects
        28
      3. group Id
        FG002
        num Subjects
        29
      4. group Id
        FG003
        num Subjects
        28
      5. group Id
        FG004
        num Subjects
        35
      6. group Id
        FG005
        num Subjects
        21
      7. group Id
        FG006
        num Subjects
        10
      8. group Id
        FG007
        num Subjects
        21
      9. group Id
        FG008
        num Subjects
        11
      10. group Id
        FG009
        num Subjects
        11
      11. group Id
        FG010
        num Subjects
        12
      12. group Id
        FG011
        num Subjects
        12
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        29
      2. group Id
        FG001
        num Subjects
        27
      3. group Id
        FG002
        num Subjects
        29
      4. group Id
        FG003
        num Subjects
        28
      5. group Id
        FG004
        num Subjects
        35
      6. group Id
        FG005
        num Subjects
        21
      7. group Id
        FG006
        num Subjects
        10
      8. group Id
        FG007
        num Subjects
        21
      9. group Id
        FG008
        num Subjects
        11
      10. group Id
        FG009
        num Subjects
        11
      11. group Id
        FG010
        num Subjects
        12
      12. group Id
        FG011
        num Subjects
        12
      type
      Treated
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      9. group Id
        FG008
        num Subjects
        0
      10. group Id
        FG009
        num Subjects
        0
      11. group Id
        FG010
        num Subjects
        0
      12. group Id
        FG011
        num Subjects
        0
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        29
      2. group Id
        FG001
        num Subjects
        28
      3. group Id
        FG002
        num Subjects
        29
      4. group Id
        FG003
        num Subjects
        28
      5. group Id
        FG004
        num Subjects
        35
      6. group Id
        FG005
        num Subjects
        21
      7. group Id
        FG006
        num Subjects
        10
      8. group Id
        FG007
        num Subjects
        21
      9. group Id
        FG008
        num Subjects
        11
      10. group Id
        FG009
        num Subjects
        11
      11. group Id
        FG010
        num Subjects
        12
      12. group Id
        FG011
        num Subjects
        12
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
In this study participants were evaluated in 5 different combinations with avelumab: Combination A, B, C, D and F. Each combination was planned to be conducted in 2 phases: Phase 1b (lead-in phase) and Phase 2 (expansion phase). Phase 2 was conducted at the selected dose level of avelumab combination which was determined safe for participants in Phase 1b.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice